|
|
|
| Research Progress of Neutralizing Antibody Drugs against SARS-CoV-2 |
SHI Rui,YAN Jing-hua( ) |
| Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101,China |
|
|
|
Abstract With the continuous spread of the COVID-19 epidemic, it is urgent to develop effective therapeutic drugs. Neutralizing antibodies, as the most promising specific therapeutics against SARS-CoV-2, are proved to be effective in clinical trials. The research progress of neutralizing antibodies were summarized, including the involved technologies, and the clinical results in order to provide benefits for developing neutralizing antibodies in emerging infectious diseases including COVID-19.
|
|
Received: 14 May 2021
Published: 06 July 2021
|
|
|
|
Corresponding Authors:
Jing-hua YAN
E-mail: yanjh@im.ac.cn
|
|
|
| [1] |
Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol, 2021, 19(3):141-154.
doi: 10.1038/s41579-020-00459-7
|
|
|
| [2] |
Wiersinga W J, Rhodes A, Cheng A C, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA, 2020, 324(8):782.
doi: 10.1001/jama.2020.12839
pmid: 32648899
|
|
|
| [3] |
Samrat S K, Tharappel A M, Li Z, et al. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research, 2020, 288:198141.
doi: 10.1016/j.virusres.2020.198141
|
|
|
| [4] |
Wang Q H, Zhang Y F, Wu L L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, 2020, 181(4): 894-904.e9.
doi: 10.1016/j.cell.2020.03.045
|
|
|
| [5] |
Costa L B, Perez L G, Palmeira V A, et al. Insights on SARS-CoV-2 molecular interactions with the renin-angiotensin system. Frontiers in Cell and Developmental Biology, 2020, 8:559841. DOI: 10.3389/fcell.2020.559841.
doi: 10.3389/fcell.2020.559841
|
|
|
| [6] |
Ehrhardt S A, Zehner M, Krähling V, et al. Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. Nature Medicine, 2019, 25(10):1589-1600.
doi: 10.1038/s41591-019-0602-4
|
|
|
| [7] |
Domachowske J B, Khan A A, Esser M T, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatric Infectious Disease Journal, 2018, 37(9):886-892.
doi: 10.1097/INF.0000000000001916
|
|
|
| [8] |
Gaudinski M R, Coates E E, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody MAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. The Lancet, 2019, 393(10174):889-898.
doi: 10.1016/S0140-6736(19)30036-4
|
|
|
| [9] |
Shi R, Shan C, Duan X M, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020, 584(7819):120-124.
doi: 10.1038/s41586-020-2381-y
|
|
|
| [10] |
Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ b cells. Cell, 2020, 182(1):73-84.
doi: 10.1016/j.cell.2020.05.025
|
|
|
| [11] |
Ju B, Zhang Q, Ge J W, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584(7819):115-119.
doi: 10.1038/s41586-020-2380-z
|
|
|
| [12] |
Chi X Y, Yan R H, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science, 2020, 369(6504):650-655.
doi: 10.1126/science.abc6952
|
|
|
| [13] |
Wang Q, Yang H, Liu X, et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science Translational Medicine, 2016, 8(369): 369ra179.
|
|
|
| [14] |
King D J, Bowers P M, Kehry M R, et al. Mammalian cell display and somatic hypermutation in vitro for human antibody discovery. Curr Drug Discov Technol, 2014, 11(1):56-64.
doi: 10.2174/15701638113109990037
|
|
|
| [15] |
Li Y, Wan Y H, Liu P P, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Research, 2015, 25(11):1237-1249.
doi: 10.1038/cr.2015.113
|
|
|
| [16] |
Yang L F, Liu W H, Yu X, et al. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Therapeutics, 2020, 3(3):205-212.
doi: 10.1093/abt/tbaa020
|
|
|
| [17] |
Jones B E, Brown-Augsburger P L, Corbett K S, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv, 2020, DOI: 10.1101/2020.09.30.318972.
|
|
|
| [18] |
Gottlieb R L, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA, 2021, 325(7):632.
doi: 10.1001/jama.2021.0202
|
|
|
| [19] |
Hansen J, Baum A, Pascal K E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, 2020, 369(6506):1010-1014.
doi: 10.1126/science.abd0827
|
|
|
| [20] |
Weinreich D M, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. New England Journal of Medicine, 2021, 384(3):238-251.
doi: 10.1056/NEJMoa2035002
|
|
|
| [21] |
Pinto D, Park Y J, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020, 583(7815):290-295.
doi: 10.1038/s41586-020-2349-y
pmid: 32422645
|
|
|
| [22] |
Bournazos S, Corti D, Virgin H W, et al. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature, 2020, 588(7838):485-490.
doi: 10.1038/s41586-020-2838-z
|
|
|
| [23] |
Dong J H, Zost S J, Greaney A J, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv, 2021, DOI: 10.1101/2021.01.27.428529.
|
|
|
| [24] |
Cheolmin K, Dong-Kyun R, Lee J H, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun, 2021, 12(1):288.
doi: 10.1038/s41467-020-20602-5
|
|
|
| [25] |
Lv Z, Deng Y Q, Ye Q, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science, 2020, 369(6510):1505-1509.
doi: 10.1126/science.abc5881
|
|
|
| [26] |
Bournazos S, Gupta A, Ravetch J V. The role of IgG Fc receptors in antibody-dependent enhancement. Nature Reviews Immunology, 2020, 20(10):633-643.
doi: 10.1038/s41577-020-00410-0
|
|
|
| [27] |
Lee W S, Wheatley A K, Kent S J, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology, 2020, 5(10):1185-1191.
doi: 10.1038/s41564-020-00789-5
|
|
|
| [28] |
Arvin A M, Fink K, Schmid M A, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature, 2020, 584(7821):353-363.
doi: 10.1038/s41586-020-2538-8
pmid: 32659783
|
|
|
| [29] |
Mackness B C, Jaworski J A, Boudanova E, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. mAbs, 2019, 11(7):1276-1288.
doi: 10.1080/19420862.2019.1633883
pmid: 31216930
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
